Prognosis
Lilly to Supply Covid Antibody to U.S. for $375 Million
- Funding hinges on FDA emergency authorization of treatment
- Government has option to purchase more vials through June
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
The U.S. government agreed to pay Eli Lilly & Co. $375 million for 300,000 vials of its experimental Covid-19 antibody as it undergoes regulatory review for emergency-use authorization.